Brief: Frequency Therapeutics, Inc. Q2 EPS USD -0.3
10/08/2023 21:32
Aug 10 (Reuters) - Frequency Therapeutics, Inc. Q2 EPS USD -0.3. * Q2 operating expenses USD 11.831 million * Q2 pretax profit USD -10.791 million * Q2 net income USD -10.796 million * Q2 income from operations USD -11.831 million
Recent news on Korro Bio
See all newsBrief: Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Korro Announces First Cohort Dosed In Phase 1/2 Clinical Trial (Anchor) For Krro-121
Brief: Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Korro Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Korro Bio, Inc. expected to post a loss of $1.43 a share - Earnings Preview